文献速递银屑病与炎症性皮肤病

托法替布治疗甲银屑病:两项52周随机对照3期研究

Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
PubMed 文献 · J Am Acad Dermatol · 2017-04-07

本文为两项相同3期研究的事后分析,评估托法替布5mg或10mg每日两次治疗中重度斑块状银屑病患者甲银屑病的疗效。第16周时,托法替布组达到NAPSI50、NAPSI75、NAPSI100的患者比例显著高于安慰剂组,改善持续至第52周。

要点

  • 托法替布5mg和10mg每日两次治疗甲银屑病,第16周疗效显著优于安慰剂。
  • 第16周NAPSI50应答率:5mg组32.8%,10mg组44.2%,安慰剂组12.0%。
  • 疗效改善持续至第52周。

核心结论

  • 托法替布治疗甲银屑病在第16周较安慰剂有显著改善,且改善维持至52周。

研究设计与样本

  • 两项相同的3期研究(OPT Pivotal 1和2)的事后分析,患者按2:2:1随机接受托法替布5mg、10mg或安慰剂每日两次。

主要发现

  • 基线平均NAPSI评分:托法替布5mg组(N=487)27.0,10mg组(N=476)27.3,安慰剂组(N=233)26.9。
  • 第16周达到NAPSI50的比例:5mg组32.8%,10mg组44.2%,安慰剂组12.0%(所有P<.05)。
  • 第16周达到NAPSI75的比例:5mg组16.9%,10mg组28.1%,安慰剂组6.8%(所有P<.05)。
  • 第16周达到NAPSI100的比例:5mg组10.3%,10mg组18.2%,安慰剂组5.1%(所有P<.05)。
  • 改善持续至第52周。

关键数值与推荐

  • NAPSI50、NAPSI75、NAPSI100分别指NAPSI较基线改善≥50%、≥75%、100%。

临床怎么用

  • 托法替布可用于改善中重度斑块状银屑病患者的甲银屑病表现,疗效可持续至52周。

局限性

  • 第28周时临床无应答者停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor. Efficacy and safety of tofacitinib in patients with moderate-to-severe plaque psoriasis have been demonstrated. OBJECTIVE: We sought to assess the efficacy of tofacitinib for the treatment of nail psoriasis over a period of 52 weeks. METHODS: In 2 identical phase 3 studies (OPT Pivotal 1 and 2), patients were randomized 2:2:1 to receive tofacitinib 5 mg, tofacitinib 10 mg, or placebo, twice daily. At week 16, placebo-treated patients were re-randomized to tofacitinib. This post hoc analysis of patients with existing nail psoriasis assessed the Nail Psoriasis Severity Index (NAPSI) score and proportions of patients achieving ≥50% reduction in NAPSI from baseline (NAPSI50), NAPSI75, or NAPSI100. RESULTS: Baseline mean NAPSI scores for patients treated with tofacitinib 5 mg (N = 487), tofacitinib 10 mg (N = 476), and placebo (N = 233) twice daily were 27.0, 27.3, and 26.9, respectively. At week 16, significantly (all P < .05) more patients receiving tofacitinib 5 mg and tofacitinib 10 mg versus placebo twice daily achieved NAPSI50 (32.8%, 44.2% vs 12.0%), NAPSI75 (16.9%, 28.1% vs 6.8%), and NAPSI100 (10.3%, 18.2% vs 5.1%), respectively. Improvements were sustained to week 52. LIMITATIONS: Limitations include discontinuation of clinical nonresponders at week 28. CONCLUSIONS: Tofacitinib treatment resulted in improvements in nail psoriasis versus placebo at week 16; improvements were maintained over 52 weeks [NCT01276639; NCT01309737].

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Merola JF, Elewski B, Tatulych S, et al. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2017. PMID: 28396102. doi:10.1016/j.jaad.2017.01.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。